Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results
Retrieved on:
Thursday, August 5, 2021
Company, Head and neck cancer, U.S. Securities and Exchange Commission, Forward-looking statement, American Association, Asco, Drug resistance, American Society of Clinical Oncology, Patent, Pancreatic cancer, Administration, Programmed cell death protein 1, Annual report, Private Securities Litigation Reform Act, AACR, Large-cell lung carcinoma, Insurance, CEACAM1, Patient, COVID-19, Celecoxib, GLOBE, Cetuximab, Legislation, Society, STAT3, Bristol Myers Squibb, Cancer, Intention, SEC, General officer, Food and Drug Administration, Hypertension, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Survival, Drug development, IRS2, SG, ESOP, CM postcode area, Annual general meeting, American Association for Cancer Research, Safety, Head, Nivolumab, Marketing, Food, Neck, Pharmaceutical industry, Cryptocurrency, Animal
REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.
Key Points:
- REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.
- We achieved significant progress in the advancement of our promising oncology pipeline during the first half of 2021, said Isaac Israel, Chief Executive Officer of Purple Biotech.
- Initial results from the first dose level cohort showed that NT219 was well-tolerated with minimal serious adverse events.
- These are factors that we believe could cause our actual results to differ materially from expected results.